Celldex Therapeutics (CLDX) Return on Capital Employed (2011 - 2026)

Celldex Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 62.36% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 3276.0% year-over-year to 62.36%; the TTM figure through Mar 2026 stood at 62.36% (down 3276.0% YoY), while the FY2025 annual figure was 45.14%, down 1204.0% from the prior year.
• Return on Capital Employed was 62.36% for Q1 2026 at Celldex Therapeutics, down from 50.89% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 5.12% in Q1 2022 to a low of 62.36% in Q1 2026.
• Historically, Return on Capital Employed has averaged 32.58% across 5 years, with a median of 33.66% in 2022.
• The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 3759 bps in 2023, then soared 2819 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 33.66% in 2022, then slumped by 34 bps to 45.21% in 2023, then jumped by 44 bps to 25.39% in 2024, then tumbled by 100 bps to 50.89% in 2025, then slipped by 23 bps to 62.36% in 2026.
• The last three Return on Capital Employed figures came in at 62.36% (Q1 2026), 50.89% (Q4 2025), and 41.07% (Q3 2025), per Business Quant data.